Great Debates in Oncology: The Use of Adjuvant/Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma - Round 2
In round 2 of Great Debates in Oncology: The Use of Adjuvant and Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma, moderated by Brian Van Tine, MD, PhD, experts Jonathan Trent, MD, PhD, and Robin Jones, BSc, MB BS, MRCP, MD (Res), debate whether the benefits of adjuvant/neoadjuvant chemotherapy outweigh the associated toxicities.
Listen to round 2 below, or read the comments.
In case you missed it, listen to round 1, where Dr Trent and Dr Jones went head-to-head on whether the quality of evidence is sufficient to support the use of adjuvant/neoadjuvant chemotherapy for localized soft-tissue sarcoma.
Up next, listen to round 3, where Dr Trent and Dr Jones debate which patient characteristics to consider when determining the appropriateness of adjuvant/neoadjuvant chemotherapy for localized soft-tissue sarcoma.
